A few years ago, Declan Rice said he would have passed. Now, however, the £105m man assumed responsibility, shot and, via a deflection off Jonny Evans, gave Arsenal a 96th-minute lead against Manchester United. As Gabriel Jesus scored an even later goal, it was not technically the winner. But Rice was the scorer of the de facto decider in the sort of match that can define seasons and establish reputations. Perhaps particularly for central midfielders, given that it is a fixture that evokes memories of Patrick Vieira against Roy Keane. Vieira scored the winning penalty in an FA Cup final shootout against United; Keane scored a disproportionate number of his United goals – five, almost 10 percent – against Arsenal. Rice’s first in Arsenal colours came at United’s expense. The most expensive Englishman ever can appear something of a throwback player: called a defensive midfielder, but often an all-rounder, in the way the Frenchman and the Irishman were. His post-match interview was conducted next to Keane who, like Graeme Souness, a similarly dominant and brilliant midfielder and another whose punditry could focus more on personalities than tactics, subscribes to the great man theory of history: as a footballing great himself, he tends to argue that matches are determined by the determination of individuals, by a willingness to seize the moment, by winning a personal battle. It suits him to argue games are won by warriors, not formations involving inverted full-backs or box midfielders. Football has grown more complex, the tactical intricacies of managers such as Mikel Arteta and Pep Guardiola reducing the significance of going mano a mano with the opposition’s alpha male. And yet, in the age of the £100m midfielder, perhaps Rice has a responsibility to be more than just another cog in the wheel, to be the match-winner at least sometimes. If it is simplistic to demand a tangible impact that always equates with his price tag for a player whose contribution stretches far beyond goals and assists, he is nevertheless charged with improving Arsenal. Turning one point into three and winning a game against rivals is a way of doing that. And if philosophies and systems seemed to have reduced the reliance on the individual, there is evidence in the midfields of Arteta and Guardiola that football can still come down to big players producing big deeds at big moments. Ilkay Gundogan spent the first half of his Manchester City career as a neat passer. In the second half, he was transformed into the man for the big occasion, the scorer supreme who could use his footballing intelligence to find space and his technique to finish. It was, in part, why he became captain; by the time of his FA Cup final brace, he felt more Roy of the Rovers than Sergio Busquets. As the defensive midfielder, Rodri’s primary responsibilities were to engineer perpetual possession and to cut off counter-attacks. Yet as the Spaniard grew in stature, he has tended to deliver crucial contributions: most obviously the Champions League final winner and most recently the superb late decider at Sheffield United but a pre-Rice Arsenal can probably still remember and regret his injury-time winner at the Emirates Stadium on New Year’s Day in 2022: if the sense is that managers like Guardiola and Arteta want their midfielders to be elegantly robotic, executing a strategy with practised excellence, the importance of individual interventions is still apparent. Rice need only gaze across the Arsenal midfield to see. Martin Odegaard joined with certain similarities to Gundogan: obviously an assured passer, he has turned himself into an accomplished scorer as well as a regular skipper. The Norwegian’s two goals this season, a nerveless penalty at Crystal Palace and a swift equaliser against United, were signs of his substance, of a capacity to deliver when it matters. That Rice did likewise feels auspicious. He has cost the sort of sum that used to be reserved for attackers. Chelsea created the £100m midfielder and now have two of them, a £222m double act. That can seem the product of a shift in thinking, recognising the significance of dictating a game. But there is still the need to decide it. Enzo Fernandez has shown his incisive passing as he has become increasingly creative: that he only has two assists in their colours is in part a reflection of others’ poor finishing. But the Argentinian has a lone goal himself, and that was against AFC Wimbledon of League Two, while he missed a penalty at West Ham. Moises Caicedo’s Chelsea career has only spanned 205 minutes on the pitch and, while Fernandez has been used as a No 10 of late, the Ecuadorian’s deeper role means he is likely to score fewer goals than the World Cup winner or Rice. Nevertheless, at such a colossal cost, each was bought to make a difference. And when, deep into added time, it seemed Arsenal would drop two points, Rice did. Read More Arrest after Roy Keane allegedly headbutted at Emirates Stadium Arsenal forward Gabriel Jesus hopes he has seen the last of knee niggles Declan Rice rises to the moment as Arsenal avoid disastrous slip-up

VANCOUVER, British Columbia--(BUSINESS WIRE)--May 25, 2023--

Here's a sneak peek into the bombshell moments shared by John Stamos in his latest memoir

A former prime minister of Slovakia who plans to end the country’s military support for Ukraine is poised to return to office after his political party signed a coalition government deal with two other parties

One of the scientists whose work pioneered the development of medications such as Ozempic and Wegovy has revealed why life may become “so miserably boring” after two years of using the drug. Ozempic is an FDA-approved medication used for the treatment of type 2 diabetes. It works by mimicking a hormone called glucagon-like peptide 1 (GLP-1), which regulates blood sugar levels and slows down the rate at which food leaves the stomach, often creating the feeling of fullness. These semaglutide injections – sold under the brand names Ozempic and Wegovy – have soared in popularity as many people, including Hollywood celebrities, have used it for weight loss. What’s more, people have also found Ozempic has been effective in curing their addictive habits, like drinking, smoking, shopping, or nail biting. However, because of Ozempic’s increasing popularity, it has led to national shortages of the type 2 diabetes treatment – leaving those who actually need it without. In an interview with Wired, professor Jens Juul Holst – who received the Warren Alpert Foundation Prize in 2021 for his work developing treatments based on the GLP-1 hormone – spoke about the effects of Ozempic, and why he believes many people will stop taking the medication after just a few years. “What happens is that you lose your appetite and also the pleasure of eating, and so I think there’s a price to be paid when you do that,” Holst told Wired. “If you like food, then that pleasure is gone. The craving for food for some people is taken away when they take GLP-1 drugs.” He continued: “That may eventually be a problem, that once you’ve been on this for a year or two, life is so miserably boring that you can’t stand it any longer and you have to go back to your old life.” Holst added that medications like Ozempic and Wegovy have been on the market since 2005, though studies show that these people don’t stay on them for very long. “It’s just like every other drug, they don’t stay on it for many reasons,” he explained. “One of the reasons, as I said, is that once you have tried it and you realise you’ve lost interest in food, then that may be enough.” “We don’t know why people stop taking these drugs, but we know for a fact that they do stop. They do that all over the world.” A 2020 study found that 70 per cent of people who took GLP-1 drugs for type 2 diabetes stopped taking them within two years. However, this could pose a problem for many patients taking semaglutide injections. Research has found that people who stopped taking Ozempic or Wegovy for weight loss experienced weight rebound. A trial published in April 2022 saw participants gain back two thirds of the weight they had lost after 68 weeks of taking semaglutide. As for celebrities who use the once-weekly injection for weight loss, despite not having diabetes or clinical obesity, Hans instead called attention to the “many terrible problems” that those with diabetes have struggled with by not having drugs like Ozempic readily available. “Have you ever visited a diabetes hospital? It’s really deplorable,” he said. “People come in with amputated limbs and compromised cognitive functions and heart problems or they can barely move – they’re miserable and depressed. It’s really serious. There is so much you can improve with a drug that is not only a weight-loss drug but is also an anti-diabetic.” Amidst the popularity of semaglutide injections, the US Food and Drug Administration has issued warnings for consumers not to use off-brand versions of Ozempic or Wegovy, because they may not include the same GLP-1 hormone used in approved medications. Earlier this month, agency officials reported problems with patients using compounded versions of semaglutide – which combines traditional semaglutide with other ingredients. These drugs are not FDA-approved, and the agency does not verify the safety or effectiveness of compounded drugs. Consumers should only use drugs containing semaglutide with a prescription from a licensed health care provider and obtained from a state-licensed pharmacy or other facilities registered with the FDA, the agency said. Read More What is ‘Ozempic face’? Doctors warn about facial ageing side effect of diabetes medications How does Wegovy work? The ‘game changing’ weight loss drug beloved by Hollywood FDA warns against using off-brand versions of Ozempic, Wegovy for weight loss Pregnant Stassi Schroeder admits she wants to ‘try’ Ozempic after giving birth Doctors warn about ‘Ozempic face’ side effect of medications Amy Schumer says she stopped taking Ozempic because of side-effects

Extreme heat from a high-pressure system named Cerberus — after the three-headed hound from Dante’s inferno — is

Robin Gosens has scored twice after his first ever Bundesliga start in 10-man Union Berlin’s 4-1 win at Darmstadt

Six-year-old Wadea Al-Fayoume will be laid to rest in Illinois on Monday, a day after he was fatally stabbed.

By Stephanie Kelly and Jarrett Renshaw NEW YORK (Reuters) -The U.S. Environmental Protection Agency is seeking a short-term delay to

Canadian Prime Minister Justin Trudeau has announced several support measures for Ukraine including military, economic and humanitarian assistance

Are you ready to embrace the summer?

Everton signed Belgium striker Romelu Lukaku from Chelsea for a club record £28million on this day in 2014. The move came after a successful loan spell at Goodison Park the previous season in which the forward scored 16 goals in 33 appearances and helped the club finish fifth in the Premier League. The then 21-year-old, who had also spent an impressive year on loan at West Brom since joining Chelsea from Anderlecht for £18million in 2011, signed a five-year contract with the Toffees. “I decided very quickly I wanted to come back here because it was a good step for me,” said Lukaku. “This is the place I belong. “I’m 21, I need to be playing in a good team. I needed to be in a place that felt right.” The fee paid by Everton shattered their previous club record of £15million for Marouane Fellaini in 2008. Manager Roberto Martinez said: “It is not just one of those important days for the season, but it is a very significant day in the history of our football club. “It is fair to say Romelu was our number one target to bring in and the pursuit was relentless, but it had to be a record transfer and it is worth every single penny and effort we put behind it.” Lukaku spent a further three years with Everton, taking his overall tally across two spells at the club to 87 goals in 166 appearances, before joining Manchester United for £75million. He later moved to Inter Milan and then back to Chelsea. He is now back with the Blues after spending last season on loan at Inter. Read More Charity boss speaks out over ‘traumatic’ encounter with royal aide Ukraine war’s heaviest fight rages in east - follow live